Silver Spring, Maryland—(ENEWSPF)—October 31, 2017
By: Stephanie Caccomo, FDA Media
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, M.D.,…
